RAYNOR DANIEL 4
4 · ANI PHARMACEUTICALS INC · Filed Mar 19, 2018
Insider Transaction Report
Form 4
RAYNOR DANIEL
Director
Transactions
- Sale
Common Stock
2018-03-15$61.50/sh−1,902$116,973→ 294,316 total(indirect: See Footnote) - Sale
Common Stock
2018-03-19$60.62/sh−5,313$322,074→ 289,003 total(indirect: See Footnote)
Footnotes (3)
- [F1]This transaction was executed in multiple trades at prices ranging from $61.00 to $62.10. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).
- [F3]This transaction was executed in multiple trades at prices ranging from $60.50 to $60.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.